Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data

seekingalpha06-12

Citi has opened a 30-day upside catalyst watch on Alnylam (NASDAQ:ALNY) ahead of the expected release of topline results from a Phase 3 study of the company’s drug Amvuttra in the treatment of ATTR-CM...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443564518?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/865888814/image_865888814.jpg","is_english":true,"pubTime":"2024-06-12 22:55","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2443564518","market":"sh","top_or_hot":-1,"title":"Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data","media":"seekingalpha","content":"<div>\n<p>Citi has opened a 30-day upside catalyst watch on Alnylam (NASDAQ:ALNY) ahead of the expected release of topline results from a Phase 3 study of the company’s drug Amvuttra in the treatment of ATTR-CM...</p>\n\n<a href=\"https://seekingalpha.com/news/4115223-citi-opens-upside-catalyst-watch-on-alnylam-ahead-of-attr-cm-data\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Citi opens upside catalyst watch on Alnylam ahead of ATTR-CM data</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCiti opens upside catalyst watch on Alnylam ahead of ATTR-CM data\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-12 22:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4115223-citi-opens-upside-catalyst-watch-on-alnylam-ahead-of-attr-cm-data><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Citi has opened a 30-day upside catalyst watch on Alnylam (NASDAQ:ALNY) ahead of the expected release of topline results from a Phase 3 study of the company’s drug Amvuttra in the treatment of ATTR-CM...</p>\n\n<a href=\"https://seekingalpha.com/news/4115223-citi-opens-upside-catalyst-watch-on-alnylam-ahead-of-attr-cm-data\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://seekingalpha.com/news/4115223-citi-opens-upside-catalyst-watch-on-alnylam-ahead-of-attr-cm-data","article_id":"2443564518","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/865888814/image_865888814.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443564518","pubTimestamp":1718204144,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Citi has opened a 30-day upside catalyst watch on Alnylam  ahead of the expected release of topline results from a Phase 3 study of the company’s drug Amvuttra in the treatment of ATTR-CM. The investment bank said it believes the Street has underestimated the potential for the study’s success, creating a positive risk/reward. The topline results are expected in late June, early July. Citi said data from the study, called HELIOS-B, will be “transformational” for the company. It noted that Amvuttra is already a big seller for Alnylam and positive results would allow for a label expansion for ATTR-CM, which it calls a “mega-blockbuster opportunity.” Citi believes the study will meet its co-primary endpoints in monotherapy and overall population, along with demonstrating positive mortality trends. It also sees up to 40% upside to the stock if the trial is successful. Other developers of drugs to treat ATTR-CM include Pfizer  and BridgeBio .","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4550":"红杉资本持仓","BK4568":"美国抗疫概念","SG9999001176.USD":"United Global Healthcare Acc USD","PFE":"辉瑞","BK4207":"综合性银行","CM":"加拿大帝国商业银行","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","BK4505":"高瓴资本持仓","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4581":"高盛持仓","BBIO":"BridgeBio Pharma, Inc.","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4548":"巴美列捷福持仓","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SG9999002232.USD":"Allianz Global High Payout USD","BK4592":"伊斯兰概念","ALNY":"阿尔尼拉姆制药公司","SG9999002224.SGD":"Allianz Global High Payout SGD","LU0058720904.USD":"联博国际健康护理基金A","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2"},"translate_title":"花旗在ATTR-CM数据公布前对Alnylam进行上行催化剂观察","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1,"ALNY":1,"PFE":1,"CM":1},"content_text":"Citi has opened a 30-day upside catalyst watch on Alnylam (NASDAQ:ALNY) ahead of the expected release of topline results from a Phase 3 study of the company’s drug Amvuttra in the treatment of ATTR-CM. The investment bank said it believes the Street has underestimated the potential for the study’s success, creating a positive risk/reward. The topline results are expected in late June, early July. Citi said data from the study, called HELIOS-B, will be “transformational” for the company. It noted that Amvuttra is already a big seller for Alnylam and positive results would allow for a label expansion for ATTR-CM, which it calls a “mega-blockbuster opportunity.” Citi believes the study will meet its co-primary endpoints in monotherapy and overall population, along with demonstrating positive mortality trends. It also sees up to 40% upside to the stock if the trial is successful. Other developers of drugs to treat ATTR-CM include Pfizer (PFE) and BridgeBio (BBIO).","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.2","shortVersion":"4.24.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443564518"}